Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir in Egyptian Children with HCV Genotype 4
NCT03743727Phase 4Unknown
- Sponsor
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Harvoni in hepatitis C (HCV), sponsored by Yassin Abdelghaffar Charity Center for Liver Disease and Research. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 12 weeks and Sustained Viral Clearance. Status: unknown.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03743727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743727.